share_log

DEFA14A: Others

DEFA14A: Others

DEFA14A:其他
美股SEC公告 ·  11/01 17:12

Moomoo AI 已提取核心信息

Conduit Pharmaceuticals Inc. has filed Supplement No. 1 to the definitive proxy statement for its 2024 virtual annual meeting of stockholders with the U.S. Securities and Exchange Commission. This filing, dated October 28, 2024, includes amendments to correct scrivener's errors in two paragraphs related to corporate governance and director independence. The company's board has affirmed that all directors, except for three named individuals, meet the independence criteria set by Nasdaq listing standards. Currently, the board has an equal number of independent and non-independent members due to a recent resignation. The board is actively seeking to appoint an additional independent director by December 18, 2024, to comply with Nasdaq's requirement for the Audit Committee composition. The proxy materials for the annual meeting are available online for stockholders.
Conduit Pharmaceuticals Inc. has filed Supplement No. 1 to the definitive proxy statement for its 2024 virtual annual meeting of stockholders with the U.S. Securities and Exchange Commission. This filing, dated October 28, 2024, includes amendments to correct scrivener's errors in two paragraphs related to corporate governance and director independence. The company's board has affirmed that all directors, except for three named individuals, meet the independence criteria set by Nasdaq listing standards. Currently, the board has an equal number of independent and non-independent members due to a recent resignation. The board is actively seeking to appoint an additional independent director by December 18, 2024, to comply with Nasdaq's requirement for the Audit Committee composition. The proxy materials for the annual meeting are available online for stockholders.
Conduit Pharmaceuticals Inc.已向美国证券交易委员会提交了关于其 2024 年股东虚拟年会的补充文件编号 1 的确定性代理文件。此份文件的日期为 2024 年 10 月 28 日,其中包括对两个与公司治理和董事独立性有关的段落进行修正以纠正书写错误。公司董事会确认除三个特定人员外,所有董事均符合纳斯达克上市标准所设定的独立标准。目前,由于最近一位董事的辞职,董事会中独立和非独立成员人数相等。董事会正积极寻求在 2024 年 12 月 18 日之前任命一名额外的独立董事,以符合纳斯达克对审计委员会构成的要求。股东可在线获取年会的代理材料。
Conduit Pharmaceuticals Inc.已向美国证券交易委员会提交了关于其 2024 年股东虚拟年会的补充文件编号 1 的确定性代理文件。此份文件的日期为 2024 年 10 月 28 日,其中包括对两个与公司治理和董事独立性有关的段落进行修正以纠正书写错误。公司董事会确认除三个特定人员外,所有董事均符合纳斯达克上市标准所设定的独立标准。目前,由于最近一位董事的辞职,董事会中独立和非独立成员人数相等。董事会正积极寻求在 2024 年 12 月 18 日之前任命一名额外的独立董事,以符合纳斯达克对审计委员会构成的要求。股东可在线获取年会的代理材料。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息